King & Spalding represented one of the largest global medical device companies in a multi-national FCPA internal investigation in five European countries, China, Brazil, and elsewhere. We advised on the design and implementation of an updated global anti-corruption compliance program. We represented the company in response to parallel investigations by the DOJ and SEC, resulting in prosecution declinations from both agencies.